OncosphereApprovals · for clinicians
FDA oncology approvals, October 2026: a roundup
A busy month for US approvals. Summarised from the FDA’s oncology approval notifications:
| Date (2026) | Drug | Indication |
|---|---|---|
| 2 Oct | Pirtobrutinib (Jaypirca) | Previously untreated CLL/SLL with no known 17p deletion |
| 7 Oct | Tucatinib + trastuzumab + pertuzumab | Maintenance after induction in unresectable locally advanced or metastatic HER2-positive breast cancer |
| 8 Oct | Atezolizumab (Tecentriq / Tecentriq Hybreza) + fluoropyrimidine + oxaliplatin | Adjuvant treatment of Stage III dMMR colon cancer |
| 14 Oct | Nogapendekin alfa inbakicept (Anktiva) + BCG | BCG-unresponsive NMIBC — expanded to include high-grade papillary-only tumours |
| 16 Oct | Pembrolizumab (Keytruda / Keytruda Qlex) | Traditional approval for previously treated TMB-H (≥13 mut/Mb) solid tumours with no satisfactory alternatives |
| 19 Oct | Dostarlimab (Jemperli) | Accelerated approval for Stage II/III MSI-H/dMMR locally advanced rectal cancer |
| 26 Oct | Talazoparib (Talzenna) + enzalutamide | Metastatic androgen pathway modulation-naïve or -sensitive (hormone-sensitive) prostate cancer with HRR gene mutations |
Why it matters
Two approvals (atezolizumab in colon cancer, dostarlimab in rectal cancer) reinforce universal MMR/MSI testing of colorectal cancers at diagnosis — something we can do with immunohistochemistry in most centres.
Notes on each approval
- Pirtobrutinib (first-line CLL/SLL): a non-covalent BTK inhibitor, previously used after covalent BTK inhibitors. The first-line label applies to patients without 17p deletion; BRUIN CLL-313 (n=282) vs bendamustine–rituximab: median PFS not estimable vs 33.5 mo, HR 0.20 (95% CI 0.11–0.37); OS immature. Dose 200 mg once daily. Watch infections, bleeding, cytopenias, arrhythmias. Caveat: beating BR does not prove superiority over covalent BTK inhibitors or fixed-duration venetoclax regimens.
- Tucatinib maintenance: adds an oral HER2 tyrosine-kinase inhibitor to HP maintenance after first-line induction — relevant given the frequency of brain metastases in HER2-positive disease. HER2CLIMB-05 (n=654; no progression after 4–8 cycles of THP induction; brain metastases allowed; endocrine therapy allowed if HR+): median PFS 24.9 vs 16.3 mo, HR 0.64 (95% CI 0.51–0.80), p<0.0001; OS immature. Tucatinib 300 mg BD. Boxed warning for hepatotoxicity; watch diarrhoea and a creatinine rise that does not reflect true renal dysfunction.
FDA approval notice, 7 Oct 2026. HR 0.64 (0.51–0.80).
- Adjuvant atezolizumab in dMMR colon cancer: the first immunotherapy approval in the curative colon setting, based on adding atezolizumab to FOLFOX-type chemotherapy in stage III dMMR disease. ATOMIC (n=712): 3-yr DFS 86.3% vs 76.2%, HR 0.50 (95% CI 0.35–0.73); 6 mo atezolizumab + mFOLFOX6, then 6 mo atezolizumab alone. Grade 3–4 AEs 84.1% vs 71.9%. Do not extrapolate to pMMR or stage II.
As summarised by Dr. Senthil Kumar on X (10 Oct 2026); check the FDA notice for the label.
- Nogapendekin alfa + BCG: an IL-15 superagonist for BCG-unresponsive non-muscle-invasive bladder cancer; the label now includes papillary-only high-grade disease. Note the evidence basis: FDA extrapolated from the CIS cohort (QUILT-3.032 cohort A, n=77: CR 62%, 58% of responders with DoR ≥12 mo, 40% ≥24 mo) rather than requiring a separate approval trial. For papillary-only disease, cohort B (n=80, J Urol): DFS 58.2% at 12 mo, 52.1% at 24 mo, 38.2% at 36 mo; PFS 83.1% and cystectomy avoidance 81.8% at 36 mo. Dose 400 mcg intravesical with BCG weekly ×6 induction, then maintenance up to 37 months. Label warns that delaying cystectomy can lead to metastatic disease.
- Pembrolizumab TMB-H: conversion from accelerated to traditional approval, with the cut-off raised from ≥10 to ≥13 mut/Mb because benefit was not confirmed at TMB 10 to <13. KEYNOTE-158 (n=220 with TMB ≥13; 145 in prospective cohort M, 75 from cohorts A–J): ORR 36% (95% CI 30–43); 58% of responses lasted ≥12 months. TMB-H is uncommon and benefit varies by tumour type — it is a last-line, not a first-line, biomarker in most cancers. Re-check old reports that called TMB 10–12 “high”.
- Dostarlimab (dMMR rectal): see the separate post.
- Talazoparib + enzalutamide (HRR-mutated mHSPC), added 30 Oct: moves the TALAPRO-2 combination into the hormone-sensitive setting. TALAPRO-3 (n=599, double-blind, all on continuous ADT; HRR genes ATM, ATR, BRCA1/2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, RAD51C by tissue or ctDNA NGS): investigator-assessed rPFS median not reached vs 45.8 mo, HR 0.48 (95% CI 0.36–0.65), p<0.0001; OS immature. Pfizer reports benefit in both BRCA and non-BRCA subgroups and grade ≥3 anaemia in 51% vs 3% (5% stopped talazoparib for anaemia). Talazoparib 0.5 mg OD with enzalutamide 160 mg. Practical point: this makes upfront germline plus tumour/ctDNA HRR testing part of mHSPC workup; plan for transfusions and blood counts.
FDA approval notice, 26 Oct 2026. HR 0.48 (0.36–0.65); control median rPFS 45.8 mo.
How to use FDA news in India
FDA approval tells us an agency judged the benefit-risk acceptable in the US. It does not mean the drug is approved by CDSCO, affordable, or covered by government schemes. Many of these drugs have no Indian price yet — check current availability before discussing them with patients.
Key efficacy figures above are taken from the FDA approval notices (and the cited trial publications); check the full prescribing information on Drugs@FDA before use.
These are US FDA decisions. Approval and availability in India (CDSCO) may differ.
Sources
- Dr. Senthil Kumar on X — October 2026 oncology updates thread (ATOMIC, BRUIN CLL-313)
- FDA — Oncology/Hematologic Malignancies Approval Notifications
- FDA approves atezolizumab with chemotherapy for Stage III dMMR colon cancer
- FDA approves tucatinib with trastuzumab and pertuzumab for maintenance in HER2-positive breast cancer
- FDA grants traditional approval for pembrolizumab in TMB-H solid tumors
- FDA approves talazoparib with enzalutamide for mAPMN/S prostate cancer with HRR gene mutations (26 Oct 2026)
- Pfizer press release — TALZENNA plus XTANDI approved in mAPMN/S prostate cancer (TALAPRO-3)
- FDA approves an expanded indication for nogapendekin alfa inbakicept-pmln (14 Oct 2026)
- QUILT-3.032 cohort B 36-month follow-up, J Urol (papillary-only BCG-unresponsive NMIBC)
Educational summary, not medical advice. Opinions are labelled as such and are the author's own. Approvals and availability in India (CDSCO) may differ from the US/EU.